Abstracts Archive - Page 129 of 2607 - ACR Meeting Abstracts

Abstract Number: 1867 • ACR Convergence 2025
Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
Laura Much¹, Elena Pachera², Havard Fretheim³, Knut EA Lundin⁴, Lumeng Li⁵, Astrid Hofman⁶, Pietro Bearzi⁵, Philip Stauffer¹, Michael Scharl⁷, Oyvind Molberg⁸, Oliver Distler⁹ and Anna-Maria Hoffmann-Vold³, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Oslo, Norway, ⁴Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ⁶Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Oslo University Hospital, Oslo, Nepal, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: SSc frequently results in serious gastrointestinal (GI) complications that contribute to increased morbidity and mortality. Understanding the molecular changes across different disease stages is…
Abstract Number: 1794 • ACR Convergence 2025
OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
Gabriella Dyson¹, Montana Barrett¹, Nicholas Hanebutt¹, Aleksander Szymczak², Cindy Miranda Brawner¹, Pratibha Dube³, Ausitn Lopez¹, Padmaja Mehta-d'Souza¹ and Matlock Jeffries², ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Edmond, OK
Background/Purpose: MRL/MpJ (MRL) mice are protected from developing post-traumatic osteoarthritis (OA) histologic changes. We have previously shown the gut microbiome to play a key role…
Abstract Number: 1812 • ACR Convergence 2025
Inflammasome and UPR activation in monocytes of HLA B27 positive children with Enthesitis related arthritis category of JIA
Shivika Guleria¹ and Amita Aggarwal², ¹SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA like Spondyloarthritis (SpA).…
Abstract Number: 1792 • ACR Convergence 2025
OA protection in African spiny (Acomys) mice is partially mediated by the gut microbiome and is transferrable to wild-type mice via microbiome transplantation
Gabriella Dyson¹, Montana Barrett¹, Nicholas Hanebutt¹, Aleksander Szymczak², Cindy Miranda Brawner¹, Pratibha Dube³, Padmaja Mehta-d'Souza¹, Ashley Siefert⁴ and Matlock Jeffries², ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Edmond, OK, ⁴University of Kentucky, Lexington, KY
Background/Purpose: Mounting evidence suggests that gut microbiome shifts may be associated with knee osteoarthritis (OA) development. We have previously shown that gut microbiome transplantation from…
Abstract Number: 1837 • ACR Convergence 2025
Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
John D. Mountz¹, Kathryn Sullivan², Shanrun Liu², Cynthia Liu², Min Gao², Walter Winn Chatham³, Tanecia Mitchell² and Hui-Chen Hsu², ¹University Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease, with a 9:1 female-to-male ratio. Our previous studies indicated that increased T-bet+ age-related B…
Abstract Number: 1872 • ACR Convergence 2025
High-throughput Screening Uncovers Distinct Molecular Signatures Linked with HRCT Patterns in SARD-ILD
Philip Stauffer¹, Vyacheslav Palchevskiy², Laura Much³, Phuong Diep⁴, Magdalena Abel⁴, Natasha Moe⁴, Thomas Gaisl⁵, Carolin Steinack⁵, Shahrzad Lari², Elena Pachera⁶, Øyvind Molberg⁷, Oliver Distler⁸, S. Samuel Weigt², John A. Belperio² and Anna-Maria Hoffmann-Vold⁴, ¹University of Zurich Hospital, Schlieren, Switzerland, ²UCLA, Los Angeles, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway, ⁵USZ, Zürich, Switzerland, ⁶University Hospital Zurich, Zurich, Switzerland, ⁷Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: High-Resolution Computed Tomography (HRCT) is crucial for diagnosing and managing interstitial lung disease associated with systemic autoimmune rheumatic diseases (SARD-ILD), as it reveals characteristic…
Abstract Number: 1848 • ACR Convergence 2025
DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
Nanako NIshiyama¹, Atsushi Manno¹, Tomohiro Honda², Shigeko Uryu¹, Yuichiro Imamura², Ryutaro Fukui³, Yusuke Murakami⁴, Kensuke Miyake⁵ and Yoshiaki Tomimori⁶, ¹Daiichi Sankyo Co., Ltd., Tokyo, Tokyo, Japan, ²Daiichi Sankyo Co., Ltd., Tokyo, Japan, ³Chiba University, Tokyo, Japan, ⁴Musashino University, Tokyo, Japan, ⁵Chiba University, Chiba, Japan, ⁶Daiichi Sankyo, Inc., Basking Ridge, NJ
Background/Purpose: Toll-like receptor (TLR) 7 is a pattern recognition receptor that recognizes nucleic acids and is implicated in the pathogenesis of systemic lupus erythematosus (SLE).…
Abstract Number: 1836 • ACR Convergence 2025
Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis
Jennifer Tiaré Balderas Miranda¹, Yatzil Reyna Juárez², Beatriz Alcalá-Carmona³, Nancy R Mejía Domínguez⁴, María José Ostos Prado³, José Luis Maravillas-Montero⁵, Fabiola Cassiano-Quezada⁶, Guillermo Juárez Vega⁴, karina santana⁷, Jiram Torres Ruiz⁸ and Diana Gómez-Martín⁹, ¹Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ²Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ³Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁴Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Tlalpan, Distrito Federal, Mexico, ⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁷INCMNSZ, Ciudad de México, Federal District, Mexico, ⁸INCMNSZ, Mexico, Federal District, Mexico, ⁹INCMNSZ, Mexico city, Federal District, Mexico
Background/Purpose: B cells play an essential role in lupus nephritis (LN) pathogenesis. However, abnormalities in specific subtypes like age-associated B cells (ABCs) and double negative…
Abstract Number: 1768 • ACR Convergence 2025
TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
Lea Dionet¹, Alexandre Lanau², Paul Breillat³, Quentin Delcros⁴, Federica Pallotti⁵, Margot Poux⁶, Pierre Isnard¹, Arthur Lavigne⁴, Xavier Puéchal⁷, alexandre karras⁸, Jean-Paul Duong⁹, Olivia Lenoir¹⁰, Pierre-Louis Tharaux¹¹ and Benjamin Terrier¹², ¹INSERM, Paris, France, ²Institut Curie, Paris, France, ³INSERM, PARIS ¹⁷, Ile-de-France, France, ⁴AP-HP, Paris, France, ⁵Internal Medicine and Clinical Immunology, Rennes, France, ⁶Université de Paris, PARIS ⁰⁴EME, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁸HEGP - assistance publique hopitaux de paris, paris, France, ⁹INSERM, Paris, ¹⁰Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ¹¹Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ¹²Cochin Hospital, Paris, France
Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…
Abstract Number: 1766 • ACR Convergence 2025
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
caterina ricordi¹, Maxime Beydon², Johanne Liberatore³, Pascal Cohen⁴, bertrand Dunogue⁵, Camille Mettler⁶, Benjamin Torreau⁷, Luc Mouthon⁵, Xavier Puéchal⁸ and Benjamin Terrier⁹, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, ³Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁶Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, ⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁹Cochin Hospital, Paris, France
Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1865 • ACR Convergence 2025
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
Hanlin Yin¹, Wanyi Lin², Zhangyi zhao¹, Chenhan Jia¹ and Liangjing Lu¹, ¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China (People's Republic), ²Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: Antinuclear antibodies (ANA) are detected in over 95% of systemic sclerosis (SSc) patients. Compared to cutaneous subtype classification, autoantibody-based stratification more accurately predicts survival,…
Abstract Number: 1854 • ACR Convergence 2025
Resting-State Functional Magnetic Resonance Imaging Analysis Revealed Altered Functional Connectivity Associated with Fatigue in Systemic Lupus Erythematosus
Yujie Song¹, Nobuya Abe¹, Yuichiro Fujieda², Kodai Sakiyama¹, Yuta Inoue¹, Kenichi Miyamoto¹, Kazuro Kamada¹, Yotaro Oki¹, Maria Tada¹, Shuhei Takeyama¹, Ryo Hisada², Michihito Kono² and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Background/Purpose: Fatigue is one of the most frequent constitutional symptoms in systemic lupus erythematosus (SLE), usually accompanied with impaired quality of life. Resting-state functional magnetic…
Abstract Number: 1845 • ACR Convergence 2025
Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Noe Macias-Segura¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) significantly increases the risk of premature atherosclerosis, contributing to long-term morbidity and mortality. Traditional cardiovascular risk factors do not fully…
Abstract Number: 1839 • ACR Convergence 2025
Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
Christopher Sisk¹, Loqmane Seridi², Alan Perlman³, Matthew Loza², Sheng Gao², Thomas Parker⁴, Daniel Levine⁴, Thangamani Muthukumar⁵, Yonatan Bardash⁶, Benjamin Horowitz⁷, Surya Seshan⁵ and James Chevalier³, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ²Johnson & Johnson, Spring House, PA, ³The Rogosin Institute, New York, NY, ⁴The Rogosin Institute, Weill Cornell Medical College, New York, NY, ⁵Weill Cornell Medical College, New York, NY, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷Columbia University Medical Center, New York, NY
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), associated with significant morbidity and mortality. IgA nephropathy (IgAN) is the most…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].